Scientific KnowledgeAnimal study (in vivo)MouseAnimal study (in vivo)Mouse
ZC
Zheng-Yi Chen
Associate Professor of Otolaryngology, Harvard Medical School / Mass Eye and Ear
AAV vector engineering and gene therapy delivery for inherited and acquired hearing loss.
Explore connections· click any item to explore
Laboratory1
Papers (2)
Identification of Adeno-Associated Viral Vectors That Target Neonatal and Adult Mammalian Inner Ear Cell Subtypes.
Human gene therapy · 2016
Screened 12 AAV serotypes in the mouse inner ear to map which vectors best reach hair cells and supporting cells, foundational work for cochlear gene therapy delivery.
Treatment of monogenic and digenic dominant genetic hearing loss by CRISPR-Cas9 ribonucleoprotein delivery in vivo.
Nature communications · 2023
Liposome-delivered CRISPR-Cas9 selectively cuts a dominant deafness allele in the mouse cochlea, rescuing hair cells and hearing, including in mice with two independent deafness mutations at once.